Full text is available at the source.
Abstract
Safety outcomes associated with semaglutide or liraglutide initiation for weight management remain uncertain.
- Glucagon-like peptide-1 receptor agonists are prescribed for weight loss.
- There is a need to evaluate the safety of these medications in clinical practice.
- Associations were assessed in a multicentre cohort study.
- The study focused on weight-management outcomes related to semaglutide and liraglutide.
Simplified